
Opinion|Videos|May 7, 2024
Efficacy and Safety of Aflibercept 8 mg in PHOTON Trial in DMO
Author(s)Marion Munk, MD, PhD
Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.
Advertisement
Episodes in this series
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Genetic Retinoblastoma Risk Stratified by Age Among Patients with Metachronous Bilateral Conversion
2
Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation
3
Johnson & Johnson’s TECNIS PureSee EDOF IOL cleared for US market
4
Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO
5



































